BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Xiao J, Ng CH, Chan KE, Fu C, Tay P, Yong JN, Lim WH, Tan DJH, Syn N, Wong ZY, Tseng M, Chew N, Huang DQ, Dan YY, Wong VW, Loomba R, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah MD. Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD. An Umbrella Overview of Systematic Review of Meta-Analysis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.11.006] [Reference Citation Analysis]
2 Ng CH, Xiao J, Chew NWS, Chin YH, Chan KE, Quek J, Lim WH, Tan DJH, Loke RWK, Tan C, Tang ASP, Goh XL, Nah B, Syn N, Young DY, Tamaki N, Huang DQ, Siddiqui MS, Noureddin M, Sanyal A, Muthiah M. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Front Med (Lausanne) 2022;9:985803. [PMID: 36275825 DOI: 10.3389/fmed.2022.985803] [Reference Citation Analysis]
3 Ng CH, Teng ML, Chew NW, Chan KE, Yong JN, Quek J, Tan DJH, Lim WH, Lee GSJ, Wong J, Kaewdech A, Huang DQ, Wang J, Chan MY, Noureddin M, Siddiqui MS, Sanyal A, Muthiah M. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2119128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang J, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.942753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hu W, Fang L, Zhang H, Ni R, Pan G. Changing trends in the air pollution-related disease burden from 1990 to 2019 and its predicted level in 25 years. Environ Sci Pollut Res Int 2022. [PMID: 35922595 DOI: 10.1007/s11356-022-22318-z] [Reference Citation Analysis]
6 Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE, Tan DJH, Fu CE, Tang ASP, Goh LH, Devi K, Chew NWS, Mak LL, Tamaki N, Huang DQ, Noureddin M, Siddiqui MS, Loomba R, Sanyal AJ, Muthiah M. Living in the non‐alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. Aliment Pharmacol Ther. [DOI: 10.1111/apt.17121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ng C, Lee KL, Muthiah MD, Wu KX, Chioh FWJ, Tan K, Soon GST, Shabbir A, Loo WM, Low ZS, Chen Q, Tan NS, Ng HH, Dan YY, Cheung C. Endothelial‐immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease. EMBO Reports 2022;23. [DOI: 10.15252/embr.202154271] [Reference Citation Analysis]
8 Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology 2022;75:1647-61. [PMID: 34990037 DOI: 10.1002/hep.32315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
9 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
10 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076-87. [PMID: 35285529 DOI: 10.1111/apt.16808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. [PMID: 35365931 DOI: 10.1002/hep4.1935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Melis M, Tang X, Trasino SE, Gudas LJ. Retinoids in the Pathogenesis and Treatment of Liver Diseases. Nutrients 2022;14:1456. [DOI: 10.3390/nu14071456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yong JN, Ng CH, Lee CW, Chan YY, Tang ASP, Teng M, Tan DJH, Lim WH, Quek J, Xiao J, Chin YH, Foo R, Chan M, Lin W, Noureddin M, Siddiqui MS, Muthiah MD, Sanyal A, Chew NWS. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatol Int 2022. [PMID: 35320497 DOI: 10.1007/s12072-022-10319-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 24.0] [Reference Citation Analysis]
16 Oza D, Amiji MM. Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases. Macrophage Targeted Delivery Systems 2022. [DOI: 10.1007/978-3-030-84164-5_16] [Reference Citation Analysis]
17 Ng CY, Lee KL, Muthiah MD, Wu K, Chioh FWJ, Tan K, Soon GST, Shabbir A, Loo WM, Low ZS, Chen Q, Tan NS, Ng HH, Dan YY, Cheung C. Endothelial-immune crosstalk contributes to vasculopathy in non-alcoholic fatty liver disease.. [DOI: 10.1101/2021.12.13.472411] [Reference Citation Analysis]
18 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
19 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01226-X. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
20 Muthiah MD, Ng CH, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Hao Tan DJ, Yong JN, Pan X, Heng Koh JW, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.. [DOI: 10.1101/2021.10.22.21265361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract 2021:S1530-891X(21)01244-1. [PMID: 34606980 DOI: 10.1016/j.eprac.2021.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
22 Chhavi N, Ojha S, Awasthi A, Shalimar, Goel A. Serum Level of Alanine- and Aspartate-Aminotransferase Levels in Newborns in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.08.024] [Reference Citation Analysis]
23 Xia SJ, Tang LZ, Li WH, Xu ZS, Zhang LL, Cheng FG, Chen HX, Wang ZH, Luo YC, Dai AN, Fan JG. Serum syndecan-4 is associated with nonalcoholic fatty liver disease. J Dig Dis 2021. [PMID: 34374198 DOI: 10.1111/1751-2980.13037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Penna R, Lim J, Williams BL, Blackmore CC, Coy DL. Opportunistic Screening of Patients for Hepatic Steatosis: Clinical Follow-Up and Diagnostic Yield. J Am Coll Radiol 2021:S1546-1440(21)00379-3. [PMID: 34043974 DOI: 10.1016/j.jacr.2021.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 40.0] [Reference Citation Analysis]
27 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
28 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
29 Li N, Liu Y, Yu S, Hu B, Zhao H. Composite BMI and Waist-to-Height Ratio Index for Risk Assessment of Non-alcoholic Fatty Liver Disease in Adult Populations. Hepat Mon 2021;20. [DOI: 10.5812/hepatmon.103607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Stec DE, Hinds TD Jr. Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E9493. [PMID: 33327438 DOI: 10.3390/ijms21249493] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
31 Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, Fujisawa K, Matsunaga K, Shimosegawa E, Abe K. Quantitative evaluation of hepatic integrin αvβ3 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res 2020;10:118. [PMID: 33026561 DOI: 10.1186/s13550-020-00704-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Berasain C, Avila MA. Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position? Cell Mol Gastroenterol Hepatol 2021;11:291-3. [PMID: 32971038 DOI: 10.1016/j.jcmgh.2020.08.007] [Reference Citation Analysis]
33 Chen J, Deng X, Liu Y, Tan Q, Huang G, Che Q, Guo J, Su Z. Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe? Int J Biol Sci 2020;16:2367-78. [PMID: 32760204 DOI: 10.7150/ijbs.47143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]